{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:46:40Z","timestamp":1791380800134,"version":"4.3.3"},"reference-count":90,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Post-traumatic stress disorder (PTSD) has become one of the most common psychiatric diagnosis in the United States specifically within the veteran population. The current treatment options for this debilitating diagnosis include trauma-focused psychotherapies along with selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI). 1 MDMA has recently been shown as a novel therapeutic agent with promisingly results in the treatment of PTSD. MDMA is a psychoactive compound traditionally categorized as a psychedelic amphetamine that deemed a Schedule I controlled substance in the 1980s. Prior to its status as a controlled substance, it was used by psychotherapists for an array of psychiatric issues. In more recent times, MDMA has resurfaced as a potential therapy for PTSD and the data produced from randomized, controlled trials back the desire for MDMA to be utilized as an effective pharmacologic therapy in conjunction with psychotherapy. 2<\/jats:p>","DOI":"10.64719\/pb.4414","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"125-149","source":"Crossref","is-referenced-by-count":7,"title":["MDMA to Treat PTSD in Adults"],"prefix":"10.64719","volume":"51","author":[{"given":"Dustin","family":"Latimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kia","family":"Sayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Abd-Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse M.","family":"Cornett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Hoskins M et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. British Journal of Psychiatry. 2015;206(2):93\u2013100. doi: 10.1192\/bjp.bp.114.148551. doi:","DOI":"10.1192\/bjp.bp.114.148551"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Sessa B. MDMA and PTSD treatment: \u2018PTSD: from novel pathophysiology to innovative therapeutics,\u2019. Neuroscience Letters. 2017;649:176\u2013180. doi: 10.1016\/j.neulet.2016.07.004. doi:","DOI":"10.1016\/j.neulet.2016.07.004"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW. Psychotherapy Versus Pharmacotherapy For Posttraumatic Stress Disorder: systemic review and meta-analyses to determine first-line treatments. Depression and Anxiety. 2016;33(9):792\u2013806. doi: 10.1002\/da.22511. doi:","DOI":"10.1002\/da.22511"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Stein DJ, Ipser JC, Seedat S, Sager C, Amos T. Pharmacotherapy for post traumatic stress disorder (PTSD) Cochrane Database Syst. Rev. 2006;2006(1):CD002795. doi: 10.1002\/14651858.cd002795.pub2. doi:","DOI":"10.1002\/14651858.cd002795.pub2"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Akiki TJ, Abdallah CG. Are there effective psychopharmacologic treatments for PTSD? Journal of Clinical Psychiatry. 2018;80(3):18ac12473. doi: 10.4088\/JCP.18ac12473. doi:","DOI":"10.4088\/JCP.18ac12473"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Dunlap LE, Andrews AM, Olson DE. Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine. ACS Chemical Neuroscience. 2018;9(10):2408\u20132427. doi: 10.1021\/acschemneuro.8b00155. doi:","DOI":"10.1021\/acschemneuro.8b00155"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. identification of a new therapeutic class: entactogens. J. Psychoactive Drugs. 1986;18(4):305\u2013313. doi: 10.1080\/02791072.1986.10472362. doi:","DOI":"10.1080\/02791072.1986.10472362"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Amoroso T. The Psychopharmacology of \u00b13,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder. J. Psychoactive Drugs. 2015;47(5):337\u2013344. doi: 10.1080\/02791072.2015.1094156. doi:","DOI":"10.1080\/02791072.2015.1094156"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum. Psychopharmacol. 2001;16(8):589\u2013598. doi: 10.1002\/hup.348. doi:","DOI":"10.1002\/hup.348"},{"key":"ref10","unstructured":"Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology. 1988;1(4):273\u2013277."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"De La Torre R et al. Human Pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Therapeutic Drug Monitoring. 2004;26(2):137\u2013144. doi: 10.1097\/00007691-200404000-00009. doi:","DOI":"10.1097\/00007691-200404000-00009"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Abraham HD, Aldridge AM, Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology. 1996;14(4):285\u2013298. doi: 10.1016\/0893-133X(95)00136-2. doi:","DOI":"10.1016\/0893-133X(95)00136-2"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Vizeli P, Liechti ME. Safety pharmacology of acute MDMA administration in healthy subjects. J. Psychopharmacol. 2017;31(5):576\u2013588. doi: 10.1177\/0269881117691569. doi:","DOI":"10.1177\/0269881117691569"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Bershad AK, Miller MA, Baggott MJ, De Wit H. The effects of MDMA on socio-emotional processing: does MDMA differ from other stimulants? Journal of Psychopharmacology. 2016;30(12):1248\u20131258. doi: 10.1177\/0269881116663120. doi:","DOI":"10.1177\/0269881116663120"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Kamilar-Britt P, Bedi G. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals. Neuroscience and Biobehavioral Reviews. 2015;57:433\u2013446. doi: 10.1016\/j.neubiorev.2015.08.016. doi:","DOI":"10.1016\/j.neubiorev.2015.08.016"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the Potential of Psychedelics for the Treatment of PTSD. Int. J. Neuropsychopharmacol. 2020;23(6):385\u2013400. doi: 10.1093\/ijnp\/pyaa018. doi:","DOI":"10.1093\/ijnp\/pyaa018"},{"key":"ref17","unstructured":"Kalant H. The pharmacology and toxicology of \u2018ecstasy\u2019 (MDMA) and related drugs. CMAJ. 2001;165(7):917\u2013928."},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"STEELE TD, McCANN UD, RICAURTE GA. 3,4\u2010Methylenedioxymethamphetamine (MDMA, \u2018Ecstasy\u2019): pharmacology and toxicology in animals and humans. Addiction. 1994;89(5):539\u2013551. doi: 10.1111\/j.1360-0443.1994.tb03330.x. doi:","DOI":"10.1111\/j.1360-0443.1994.tb03330.x"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Freudenmann RW, \u00d6xler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006;101(9):1241\u20131245. doi: 10.1111\/j.1360-0443.2006.01511.x. doi:","DOI":"10.1111\/j.1360-0443.2006.01511.x"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Shulgin AT. The background and chemistry of MDMA. J. Psychoactive Drugs. 1986;18(4):291\u2013304. doi: 10.1080\/02791072.1986.10472361. doi:","DOI":"10.1080\/02791072.1986.10472361"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Hardman HF, Haavik CO, Seevers MH. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol. Appl. Pharmacol. 1973;25(2):299\u2013309. doi: 10.1016\/S0041-008X(73)80016-X. doi:","DOI":"10.1016\/S0041-008X(73)80016-X"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The Lancet Psychiatry. 2016;3(5):481\u2013488. doi: 10.1016\/S2215-0366(15)00576-3. doi:","DOI":"10.1016\/S2215-0366(15)00576-3"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Passie T. The early use of MDMA (\u2018Ecstasy\u2019) in psychotherapy (1977\u20131985) Drug Sci. Policy Law. 2018 Jan;vol. 4:205032451876744. doi: 10.1177\/2050324518767442. doi:","DOI":"10.1177\/2050324518767442"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Climko RP, Roehrich H, Sweeney DR, Al-Razi J. Ecstacy: a review of MDMA and MDA. International journal of psychiatry in medicine. 1986;16(4):359\u2013372. doi: 10.2190\/dcrp-u22m-aumd-d84h. doi:","DOI":"10.2190\/dcrp-u22m-aumd-d84h"},{"key":"ref25","unstructured":"Richards RN. Experience with MDA. Can. Med. Assoc. J. 1972;106(3):256\u2013259."},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Jones AL, Simpson KJ. Review article: Mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment. Pharmacol. Ther. 1999;13(2):129\u2013133. doi: 10.1046\/j.1365-2036.1999.00454.x. doi:","DOI":"10.1046\/j.1365-2036.1999.00454.x"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Andreu V et al. Ecstasy: A common cause of severe acute hepatotoxicity. J. Hepatol. 1998;29(3):394\u2013397. doi: 10.1016\/S0168-8278(98)80056-1. doi:","DOI":"10.1016\/S0168-8278(98)80056-1"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Bonsignore A, Barranco R, Morando A, Fraternali Orcioni G, Ventura F. MDMA Induced Cardio-toxicity and Pathological Myocardial Effects: A Systematic Review of Experimental Data and Autopsy Findings. Cardiovascular Toxicology. 2019;19(6):493\u2013499. doi: 10.1007\/s12012-019-09526-9. doi:","DOI":"10.1007\/s12012-019-09526-9"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Matthai SM, Sills JA, Davidson DC, Alexandrou D. Cerebral oedema after ingestion of MDMA (\u2018ecstasy\u2019) and unrestricted intake of water 5. British Medical Journal. 1996;131(7042):1359. doi: 10.1136\/bmj.312.7042.1359b. doi:","DOI":"10.1136\/bmj.312.7042.1359b"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Holmes SB, Banerjee AK, Alexander WD. Hyponatraemia and seizures after ecstasy use. Postgrad. Med. J. 1999;75(879):32\u201333. doi: 10.1136\/pgmj.75.879.32. doi:","DOI":"10.1136\/pgmj.75.879.32"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Mueller PD, Korey WS. Death by \u2018Ecstasy\u2019: The serotonin syndrome? Ann. Emerg. Med. 1998;32(31):377\u2013380. doi: 10.1016\/S0196-0644(98)70018-6. doi:","DOI":"10.1016\/S0196-0644(98)70018-6"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Doblin R, Greer G, Holland J, Jerome L, Mithoefer MC, Sessa B. A reconsideration and response to Parrott AC (2013) \u2018Human psychobiology of MDMA or \u201cEcstasy\u201d: an overview of 25 years of empirical research,\u2019. Hum. Psychopharmacol. Clin. Exp. 2014;29(2):105\u2013108. doi: 10.1002\/hup.2389. doi:","DOI":"10.1002\/hup.2389"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Danforth AL et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl). 2018;235(11):3137\u20133148. doi: 10.1007\/s00213-018-5010-9. doi:","DOI":"10.1007\/s00213-018-5010-9"},{"key":"ref34","unstructured":"Feduccia AA. Title: 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"M. Ot\u2019alora G et al. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial. J. Psychopharmacol. 2018;32(12):1295\u20131307. doi: 10.1177\/0269881118806297. doi:","DOI":"10.1177\/0269881118806297"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Goldstein RB et al. The Epidemiology of DSM-5 Posttraumatic Stress Disorder in the United States: results from the national epidemiologic survey on alcohol and related conditions-III. 2017:1\u201321. doi: 10.1007\/s00127-016-1208-5. doi:","DOI":"10.1007\/s00127-016-1208-5"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Kessler RC, Chiu WT, Demler O. Prevalence, Severity, and Comorbidity of 12-Month. 2020;62(June 2005)","DOI":"10.1001\/archpsyc.62.6.617"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Cloitre M et al. ICD-11 Posttraumatic Stress Disorder and Complex Posttraumatic Stress Disorder in the United States: a population-based study. 2019:833\u2013842. doi: 10.1002\/jts.22454. no. June 2018. doi:","DOI":"10.1002\/jts.22454"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Arnsten AFT, Raskind MA, Taylor FB, Connor DF. Neurobiology of Stress The effects of stress exposure on prefrontal cortex: Translating basic research into successful treatments for post-traumatic stress disorder. Neurobiol. Stress. 2015;1:89\u201399. doi: 10.1016\/j.ynstr.2014.10.002. doi:","DOI":"10.1016\/j.ynstr.2014.10.002"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Hendrickson RC, Raskind MA. Noradrenergic dysregulation in the pathophysiology of PTSD. Exp. Neurol. 2016;284:181\u2013195. doi: 10.1016\/j.expneurol.2016.05.014. doi:","DOI":"10.1016\/j.expneurol.2016.05.014"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Sari Y. Serotonin 1B receptors: from protein to physiological function and behavior. 2004;28:565\u2013582. doi: 10.1016\/j.neubiorev.2004.08.008. doi:","DOI":"10.1016\/j.neubiorev.2004.08.008"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Krystal JH, Neumeister A. Noradrenergic and Serotonergic Mechanisms in the Neurobiology of Posttraumatic Stress Disorder and Resilience. 2010:13\u201323. doi: 10.1016\/j.brainres.2009.03.044. doi:","DOI":"10.1016\/j.brainres.2009.03.044"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Bailey CR, Cordell E, Sobin SM, Neumeister A. Recent Progress in Understanding the Pathophysiology of Post- Traumatic Stress Disorder. 2014;27(3):221\u2013232. doi: 10.1007\/s40263-013-0051-4. doi:","DOI":"10.1007\/s40263-013-0051-4"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Pitman RK et al. Biological Studies of Posttraumatic Stress Disorder. 2016;13(11):769\u2013787. doi: 10.1038\/nrn3339. doi:","DOI":"10.1038\/nrn3339"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Averill LA, Purohit P, Averill CL, Boesl MA, Krystal JH, Abdallah CG. Glutamate Dysregulation and Glutamatergic Therapeutics for PTSD: Evidence from Human Studies. 2018;1(203):147\u2013155. doi: 10.1016\/j.neulet.2016.11.064. doi:","DOI":"10.1016\/j.neulet.2016.11.064"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Greenberg N, Brooks S, Dunn R. Latest developments in post-traumatic stress disorder: diagnosis and treatment. 2015 Apr;:147\u2013155. doi: 10.1093\/bmb\/ldv014. doi:","DOI":"10.1093\/bmb\/ldv014"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Van Ameringen M, Mancini C, Patterson B, Boyle MH. Post-Traumatic Stress Disorder in Canada. 2008;14:171\u2013181. doi: 10.1111\/j.1755-5949.2008.00049.x. doi:","DOI":"10.1111\/j.1755-5949.2008.00049.x"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat Duty in Iraq and Afghanistan, Mental Health Problems, and Barriers to Care. N Engl J Med. 2004;351(1):13\u201322.","DOI":"10.1056\/NEJMoa040603"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Wolfe J, Erickson DJ, Sharkansky EJ, King DW, King LA. Course and Predictors of Posttraumatic Stress Disorder Among Gulf War Veterans: a prospective analysis. J Consul. Clinical Psych. 1999;67(4):520\u2013528.","DOI":"10.1037\/0022-006X.67.4.520"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Schlenger WE et al. The Prevalence of Post-Traumatic Stress Disorder in the Vietnam Generation: a multimethod, multisource assessment of psychiatric disorder. 1992;5(3)","DOI":"10.1002\/jts.2490050303"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Anderson ML, Ziedonis DM, Najavits LM. Posttraumatic Stress Disorder and Substance Use Disorder Comorbidity Among Individuals With Physical Disabilities: findings from the national comorbidity survey replication. J Traumatic Stress. 2014;27(2):182\u2013191. doi: 10.1002\/jts. doi:","DOI":"10.1002\/jts"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Pagura J, Stein MB, Bolton JM, Cox BJ, Grant B, Sareen J. Comorbidity of borderline personality disorder and posttraumatic stress disorder in the U.S. population. J. Psychiatr. Res. 2010;44(16):1190\u20131198. doi: 10.1016\/j.jpsychires.2010.04.016. doi:","DOI":"10.1016\/j.jpsychires.2010.04.016"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Lebouthillier DM, Mcmillan KA, Thibodeau MA, Asmundson GJG. Types and Number of Traumas Associated With Suicidal Ideation and Suicide Attempts in PTSD: findings from a u.s. nationally representative sample. J Traumatic Stress. 2015:183\u2013190. doi: 10.1002\/jts. doi:","DOI":"10.1002\/jts"},{"key":"ref54","unstructured":"Va \/ Dod Clinical Practice Guideline For Management Of Post-Traumatic Stress. Dep. Veterans Aff. Dep. Def. 2017 U.S. Department of Veterans Affairs."},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) Washington, DC APA, Guidel. Dev. Panel Treat. Posttraumatic Stress Disord. Adults. 2017;139 doi: 10.1162\/jocn. American Psychological Association. doi:","DOI":"10.1162\/jocn"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Crawford AA et al. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. 2014:2921\u20132931. doi: 10.1007\/s00213-014-3467-8. doi:","DOI":"10.1007\/s00213-014-3467-8"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Ojero-senard A et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. 2017:3075\u20133081. doi: 10.1007\/s00213-017-4685-7. doi:","DOI":"10.1007\/s00213-017-4685-7"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Bruno G. Serotonin toxicity: a short review of the literature and two case reports involving Citalopram. 2011:507\u2013509. doi: 10.1007\/s10072-011-0546-z. doi:","DOI":"10.1007\/s10072-011-0546-z"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Villarreal G, Hamner MB, Ca\u00f1ive JM, Robert S. Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. 2016;1:1205\u20131212. doi: 10.1176\/appi.ajp.2016.15070967. D. Pharm. doi:","DOI":"10.1176\/appi.ajp.2016.15070967"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 2020 Sep; doi: 10.1176\/appi.ajp.2020.177901. doi:","DOI":"10.1176\/appi.ajp.2020.177901"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD) Int. J. Neuropsychopharmacol. 2012;15(6):825\u2013840. doi: 10.1017\/S1461145711001209. doi:","DOI":"10.1017\/S1461145711001209"},{"key":"ref62","unstructured":"Griffin CE, III, Kaye AM, Bueno FR, Kaye A D. Benzodiazepine Pharmacology and Central Nervous System\u2014Mediated Effects. 2013;504:214\u2013223."},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"A. G. S. American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae. 2019:1\u201321. doi: 10.1111\/jgs.15767. doi:","DOI":"10.1111\/jgs.15767"},{"key":"ref64","unstructured":"3,4-Methylenedioxymethamphetamine. National Library of Medicine. 2020 National Center for Biotechnology."},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Oberlender R, Nichols DE. Drug discrimination studies with MDMA and amphetamine. Psychopharmacology (Berl). 1988;95(1):71\u201376. doi: 10.1007\/BF00212770. doi:","DOI":"10.1007\/BF00212770"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Burke WJ, Kratochvil CJ. Stereoisomers in psychiatry: the case of escitalopram. Prim. Care Companion J. Clin. Psychiatry. 2002;4(1):20\u201324. doi: 10.4088\/pcc.v04n0107. doi:","DOI":"10.4088\/pcc.v04n0107"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Pantoni MM, Anagnostaras SG. Cognitive effects of MDMA in laboratory animals: a systematic review focusing on dose. Pharmacol. Rev. 2019;71(3):413\u2013449. doi: 10.1124\/pr.118.017087. doi:","DOI":"10.1124\/pr.118.017087"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Curry DW, Young MB, Tran AN, Daoud GE, Howell LL. Separating the agony from ecstasy: R(\u2013)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice. Neuropharmacology. 2018;128:196\u2013206. doi: 10.1016\/j.neuropharm.2017.10.003. doi:","DOI":"10.1016\/j.neuropharm.2017.10.003"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Bogen IL, Haug KH, Myhre O, Fonnum F. Short- and long-term effects of MDMA (\u2018ecstasy\u2019) on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo,\u201d in. Neurochemistry International. 2003;43(4\u20135):393\u2013400. doi: 10.1016\/S0197-0186(03)00027-5. doi:","DOI":"10.1016\/S0197-0186(03)00027-5"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Jones DC, Lau SS, Monks TJ. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells. J. Pharmacol. Exp. Ther. 2004;311(1):298\u2013306. doi: 10.1124\/jpet.104.069260. doi:","DOI":"10.1124\/jpet.104.069260"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Hysek CM et al. Duloxetine inhibits effects of MDMA (\u2018ecstasy\u2019) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One. 2012;7(5) doi: 10.1371\/journal.pone.0036476. doi:","DOI":"10.1371\/journal.pone.0036476"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL. Neurochemical profiles of some novel psychoactive substances. Eur. J. Pharmacol. 2013;700(1\u20133):147\u2013151. doi: 10.1016\/j.ejphar.2012.12.006. doi:","DOI":"10.1016\/j.ejphar.2012.12.006"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Dumont GJH et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc. Neurosci. 2009;4(4):359\u2013366. doi: 10.1080\/17470910802649470. doi:","DOI":"10.1080\/17470910802649470"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M. Low-dose MDMA (\u2018ecstasy\u2019) induces vasopressin secretion. Lancet. 1998;351(9118):1784. doi: 10.1016\/S0140-6736(05)78744-4. doi:","DOI":"10.1016\/S0140-6736(05)78744-4"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Wolff K et al. Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J. Psychopharmacol. 2006;20(3):400\u2013410. doi: 10.1177\/0269881106061514. doi:","DOI":"10.1177\/0269881106061514"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 2002;162(4):396\u2013405. doi: 10.1007\/s00213-002-1131-1. doi:","DOI":"10.1007\/s00213-002-1131-1"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Kreth KP, Kovar KA, Schwab M, Zanger UM. Identification of the human cytochromes P450 involved in the oxidative metabolism of \u2018Ecstasy\u2019-related designer drugs. Biochem. Pharmacol. 2000;59(12):1563\u20131571. doi: 10.1016\/S0006-2952(00)00284-7. doi:","DOI":"10.1016\/S0006-2952(00)00284-7"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Shima N, Kamata H, Katagi M, Tsuchihashi H, Sakuma T, Nemoto N. Direct determination of glucuronide and sulfate of 4-hydroxy-3-methoxymethamphetamine, the main metabolite of MDMA, in human urine. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2007;857(1):123\u2013129. doi: 10.1016\/j.jchromb.2007.07.003. doi:","DOI":"10.1016\/j.jchromb.2007.07.003"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"De La Torre R et al. Pharmacology of MDMA in humans. Ann. N. Y. Acad. Sci. 2000;914:225\u2013237. doi: 10.1111\/j.1749-6632.2000.tb05199.x. doi:","DOI":"10.1111\/j.1749-6632.2000.tb05199.x"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Delaforge M, Jaouen M, Bouille G. Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D. Environmental Toxicology and Pharmacology. 1999;7(3):153\u2013158. doi: 10.1016\/S1382-6689(99)00007-1. doi:","DOI":"10.1016\/S1382-6689(99)00007-1"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Vizeli P, Schmid Y, Prestin K, Meyer zu Schwabedissen HE, Liechti ME. Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. Eur. Neuropsychopharmacol. 2017;27(3):232\u2013238. doi: 10.1016\/j.euroneuro.2017.01.008. doi:","DOI":"10.1016\/j.euroneuro.2017.01.008"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Steuer AE, Schmidhauser C, Schmid Y, Rickli A, Liechti ME, Kraemer T. Chiral plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine and its phase i and II metabolites following controlled administration to humans. Drug Metab. Dispos. 2015;43(12):1864\u20131871. doi: 10.1124\/dmd.115.066340. doi:","DOI":"10.1124\/dmd.115.066340"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Pizarro N et al. Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites by gas chromatography\/mass spectrometry. Rapid Commun. Mass Spectrom. 2003;17(4):330\u2013336. doi: 10.1002\/rcm.919. doi:","DOI":"10.1002\/rcm.919"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Papaseit E et al. MDMA interactions with pharmaceuticals and drugs of abuse. Expert Opinion on Drug Metabolism and Toxicology. 2020;16(5):357\u2013369. doi: 10.1080\/17425255.2020.1749262. doi:","DOI":"10.1080\/17425255.2020.1749262"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Farr\u00e9 M et al. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J. Pharmacol. Exp. Ther. 2007;323(3):954\u2013962. doi: 10.1124\/jpet.107.129056. doi:","DOI":"10.1124\/jpet.107.129056"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Bouso JC, Doblin R, Farr\u00e9 M, Alc\u00e1zar M\u00c1, G\u00f3mez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J. Psychoactive Drugs. 2008;40(3):225\u2013236. doi: 10.1080\/02791072.2008.10400637. doi:","DOI":"10.1080\/02791072.2008.10400637"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of \u00b13,4-methylenedioxymethamphetamine\u2014assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. J. Psychopharmacol. 2011;25(4):439\u2013452. doi: 10.1177\/0269881110378371. doi:","DOI":"10.1177\/0269881110378371"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Mithoefer MC et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4- methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J. Psychopharmacol. 2013;27(1):28\u201339. doi: 10.1177\/0269881112456611. doi:","DOI":"10.1177\/0269881112456611"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (\u00b13,4- Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) J. Psychopharmacol. 2013;27(1):40\u201352. doi: 10.1177\/0269881112464827. doi:","DOI":"10.1177\/0269881112464827"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Mithoefer MC et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry. 2018;5(6):486\u2013497. doi: 10.1016\/S2215-0366(18)30135-4. doi:","DOI":"10.1016\/S2215-0366(18)30135-4"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:29:26Z","timestamp":1791314966000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/mdma-to-treat-ptsd-in-adults\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":90,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4414","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}